| Use of leflunomide for treatment of cytomegalovirus infection in recipients of allogeneic stem cell transplant A Gokarn, A Toshniwal, A Pathak, S Arora, A Bonda, S Punatar, L Nayak, ... Biology of Blood and Marrow Transplantation 25 (9), 1832-1836, 2019 | 20 | 2019 |
| Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia S Arora, P Vachhani, K Bachiashvili, O Jamy Leukemia & Lymphoma 62 (9), 2292-2294, 2021 | 14 | 2021 |
| Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia S Arora, C Zainaldin, S Bathini, U Gupta, S Worth, K Bachiashvili, ... Leukemia Research 117, 106844, 2022 | 8 | 2022 |
| Differences in pretreatment frailty across gastrointestinal cancers in older adults: Results from the cancer and aging resilience evaluation registry S Arora, ME Fowler, C Harmon, M Al-Obaidi, D Outlaw, R Hollis, ... JCO Oncology Practice 18 (11), e1796-e1806, 2022 | 4 | 2022 |
| Rural-urban disparities in mortality and geriatric assessment among older adults with cancer: The cancer & aging resilience evaluation (CARE) registry ME Fowler, KM Kenzik, M Al-Obaidi, C Harmon, S Giri, S Arora, ... Journal of Geriatric Oncology 14 (4), 101505, 2023 | 3 | 2023 |
| Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents C Zainaldin, S Arora, S Bathini, U Gupta, V Pandya, S Bae, S Worth, ... Leukemia & Lymphoma 63 (13), 3245-3248, 2022 | 3 | 2022 |
| Assessment of prescribing pattern of drugs and completeness of prescriptions as per the World Health Organization prescribing indicators in various Indian tertiary care centers … R Joshi, B Medhi, A Prakash, S Chandy, J Ranjalkar, HR Bright, J Basker, ... Indian Journal of Pharmacology 54 (5), 321-328, 2022 | 3 | 2022 |
| Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy. S Arora, S Giri, KN Godby, G Ravi, LJ Costa, S Bal Journal of Clinical Oncology 40 (16_suppl), e20026-e20026, 2022 | 2 | 2022 |
| Use of leflunomide for treatment of Cytomegalovirus infection in recipients of allogeneic stem cell transplant A Gokarn, A Toshniwal, A Pathak, S Arora, A Bonda, P Dwivedi, S Punatar, ... Blood 130, 1945, 2017 | 2 | 2017 |
| Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy O Jamy, S Arora, R Meredith, D Salzman, A Di Stasi, K Minagawa, ... Bone Marrow Transplantation 57 (10), 1597-1599, 2022 | 1 | 2022 |
| Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022 S Arora, P Asawa, N Kataria, LEL Hendriks, AP Desai Cancer Investigation 40 (7), 577-589, 2022 | 1 | 2022 |
| Rural-urban disparities in Geriatric Assessment (GA) impairments and mortality among older adults with cancer: Results from the Cancer and Aging Resilience Evaluation (CARE … M Fowler, K Kenzik, M Al-Obaidi, C Harmon, S Giri, S Arora, ... Journal of Clinical Oncology 40 (16_suppl), 12012-12012, 2022 | 1 | 2022 |
| Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF). S Arora, J Senapati, L Masarova, N Pemmaraju, P Bose, GM Bravo, ... Journal of Clinical Oncology 42 (16_suppl), 6572-6572, 2024 | | 2024 |
| Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome … S Arora, J Senapati, N Pemmaraju, P Bose, L Masarova, ... Blood 142, 1861, 2023 | | 2023 |
| Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy JM Waldschmidt, S Arora, T Vijaykumar, N Sotudeh, P Anand, H Stuart, ... Blood 140 (Supplement 1), 9925-9926, 2022 | | 2022 |
| Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents. C Zainaldin, S Arora, S Bathini, V Pandya, S Bae, U Gupta, S Worth, ... Journal of Clinical Oncology 40 (16_suppl), e18808-e18808, 2022 | | 2022 |
| A Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Older Patients Using Fludarabine and Total Body Irradiation O Jamy, S Arora, D Salzman, A Di Stasi, K Minagawa, S Mineishi, A Saad 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
| CLO22-037: Tumor Lysis Syndrome and Infectious Complications During Induction With Venetoclax Combined With Azacitidine or Decitabine in Patients With Acute Myeloid Leukemia S Arora, C Zainaldin, S Bathini, U Gupta, S Worth, K Bachiashvili, ... Journal of the National Comprehensive Cancer Network 20 (3.5), CLO22-037 …, 2022 | | 2022 |
| TTP or complement-mediated TMA or both? A rare diagnosis and report of a novel plasminogen gene variant NR Tiwari, S Arora, AG Tolat, SP Shaheen, VR Sharma Annals of Hematology, 1-3, 2022 | | 2022 |
| Adoptive cellular therapy in acute myeloid leukemia: Current scope and challenges S Arora, P Asawa, A Ramakrishnan, C Bachier, NS Majhail Hematology/Oncology and Stem Cell Therapy 15 (3), 12, 2022 | | 2022 |
Omer JamyUniversity of Alabama at Birmingham在 uabmc.edu 的电子邮件经过验证
